Skip to main content
OpenTrials
Completed

NCT Number: NCT04241198

Home Retinal Imaging Using NOTAL-OCT V3.0

The study will include up to 30 AMD patients, recruited by two medical centers, Tel-Aviv medical center and Assuta Hashalom medical center. At the screening visit, the patients will be imaged in their tested, eligible eye(s), using a commercial Zeiss Cirrus or Heidelberg Spectralis OCT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

TLV Medical Center

Tel Aviv, Israel

About this study

Screening visit:

For patients eligible to participate in the study, the following procedure will be done in the "screening visit" at the clinic:

  • Patient will sign the IC (Informed Consent) form
  • The following demographic and clinical data will be collected and registered in the CRF:
  • Patient's DOB and gender.
  • Patient's diagnosis in study eye(s), based on patient's medical record, including media opacity (e.g. cataract or corneal opacity, if exists).
  • Bio-microscopy testing.
  • Refraction correction by an optometrist.
  • Habitual Snellen visual acuity
  • Commercial OCT scanning using Zeiss Cirrus or Heidelberg Spectralis.

OCT scanning pattern:

  • Macular cube of at least 6X6mm (20 degrees)
  • At least 40 B-scans per cube

Setup and tutorial home visit:

The device will be delivered to the patient's home with a setup guide attached to the package. The patient will read the setup guide instructions, unpack the device, place it on a table and connect it to a power supply. Upon first usage a tutorial clip, explaining how to operate the device and self-image the eyes, will be automatically displayed on the device's external screen. Following the tutorial patients will be instructed to scan their study eye(s). A remote support service, provided by the sponsor, will be available as needed. Its phone number will be given to the patient and will be attached to the device's base.

Daily home testing:

For each eligible eye, the following procedure will be done in the "Daily testing" at the patients' homes:

  • The patients will be requested to self-scan their study eye(s) daily, using the NOTAL-OCT V3.0..
  • The patient will be able call the sponsor's remote support service, during working hours, for assistance in case of questions or problems regarding the operation the NOTAL-OCT V3.0 device.

Exit visit:

For each eligible eye, the following procedure will be done in the "Exit visit" at the clinic:

  • Bio-microscopy testing.
  • Refraction correction by an optometrist.
  • Habitual Snellen visual acuity
  • Commercial OCT scanning using Zeiss Cirrus or Heidelberg Spectralis.

OCT scanning pattern:

  • Macular cube of at least 6X6mm (20 degrees)
  • At least 40 B-scans per cube NOTAL-OCT V3.0 Scanning.

6.Patient's experience questionnaire

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability and willingness to give informed consent (IC)
  • 18 years of age or older at the time of IC
  • Tested eye(s) diagnosed with AMD
  • Visual acuity of 20/400 Snellen (6/120) or better in the study eye
  • At least one eye is with active CNV, presenting retinal fluid at the enrolment visit, undergoing active anti-VEGF treatment
  • Ability to undergo OCT testing

Exclusion criteria

NA

Treatment and study plan

Primary outcomes

  1. To describe the dynamics of retinal fluid

    Time frame: 30 days

    To describe the dynamics of retinal fluid in eyes undergoing anti-VEGF therapy as manifested in self-operated OCT in daily home testing

Secondary outcomes

  1. To evaluate patient experience when self-operating the Notal-OCT V3.0.

    Time frame: 30 days

    by a patient experience questionnaire.

  2. E. To evaluate the level of agreement between OCT images captured by Notal-OCT V3.0 and a commercial OCT

    Time frame: 30 days

    E. To evaluate the level of agreement between OCT images captured by Notal-OCT V3.0 and a commercial OCT, for the presence of fluid, in the central 10 degrees of the macula, at screening and exit visits.

Sponsors and collaborators

Lead sponsor

Notal Vision Ltd.

Industry

Registry information

Important dates

Study start
2020
Primary completion
2022
Study completion
2023
First posted
Jan 27, 2020
Registry last updated
Jun 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.